Scholar Rock Holding Corporation — FY 2022 Form 10-K
Reporting period: Year ended December 31, 2022. The filing is an annual report, not a standalone fourth-quarter report. Scholar Rock is a clinical-stage biopharmaceutical company with no approved products or product sales.
Business context and pipeline
The company develops antibodies intended to selectively inhibit growth-factor activation. Its lead programs are apitegromab, in Phase 3 development for spinal muscular atrophy (SMA), and SRK-181, in a Phase 1 trial for cancers resistant to anti-PD-(L)1 therapies. Earlier programs target fibrosis and iron-restricted anemia.
Financial results and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $33.2 million | $18.8 million |
| Research and development expense | $124.4 million | $108.5 million |
| General and administrative expense | $43.1 million | $40.3 million |
| Operating loss | $134.4 million | $129.9 million |
| Net loss | $134.5 million | $131.8 million |
| Basic and diluted net loss per share | $2.26 | $3.59 |
| Cash used in operating activities | $132.7 million | $126.8 million |
- Revenue was entirely collaboration-related; no product revenue was recorded. FY 2022 revenue included $33.2 million recognized in January 2022 when Gilead’s remaining option rights ended. The Gilead collaboration revenue was fully recognized by January 31, 2022.
- Revenue growth did not offset operating expenses. Operating margin is not a useful measure of product economics at this pre-commercial stage.
- At December 31, 2022, cash and cash equivalents were $103.3 million and marketable securities were $212.1 million, totaling $315.4 million, versus $253.0 million a year earlier. Management estimated these resources would fund operating expenses and capital expenditures into 2025, while stating additional capital would be required to complete clinical development.
- Operating cash outflow increased to $132.7 million. Financing provided $194.8 million, primarily from the June 2022 offering; investing used $171.7 million, largely reflecting marketable-security transactions.
- Debt had a $49.7 million long-term carrying value at year-end. The amended facility allows up to $100 million in total borrowings, but the additional $50 million is subject to milestones and lender discretion. The loan matures in November 2027; principal payments are scheduled to begin in December 2024, potentially later if specified milestones are met.
- Total current assets were $328.0 million and current liabilities were $36.4 million. Total liabilities were $97.9 million; stockholders’ equity was $260.2 million.
Material changes versus FY 2021
- Revenue rose 76.4%, reflecting recognition of Gilead option-related deferred revenue, rather than product sales or recurring commercial revenue.
- R&D expense increased 14.7%, chiefly from apitegromab Phase 3 trial costs and employee costs; G&A expense increased 7.1%.
- Net loss widened 2.1% to $134.5 million. Loss per share improved to $2.26 from $3.59, while weighted-average shares increased to 59.6 million from 36.7 million, reflecting equity financing and related share equivalents.
- Cash and cash equivalents declined, but the larger marketable-securities balance lifted combined cash, cash equivalents and marketable securities by $62.4 million.
Outlook, commentary and risks
- Management expected to complete SAPPHIRE Phase 3 enrollment in 2023 and report top-line results in 2024; a commercial launch in 2025 is conditional on successful results and approval. TOPAZ 36-month extension data and SRK-181 clinical and biomarker updates were expected in 2023.
- TOPAZ 24-month results were described as showing sustained improvement among nonambulatory patients receiving SMN therapy. The filing cautions that early and interim clinical results may change; Phase 3 confirmation remains essential.
- In November 2022, the company amended its debt facility, extending interest-only payments and maturity and adding potential borrowing capacity. The stated interest rate is the greater of prime plus 4.60% or 9.35%.
- In May 2022, the company reduced its workforce by 39 positions, approximately 25%, to focus on clinical-stage programs. It recorded $1.9 million in restructuring costs and $0.1 million of non-cash equity-modification expense.
- The Janssen agreement ended in July 2022 and rights reverted to Scholar Rock. Gilead’s option period ended in January 2022, with program rights returning to the company.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, continued cash burn and need for additional financing, reliance on third-party manufacturers (including a single-source drug-substance supplier for apitegromab and SRK-181), competition, and potential dilution. Two European patents are subject to opposition proceedings.
- The company reported no material legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not provide an internal-control attestation because of the company’s reporting status.
Important facts for investors to verify
- Progress, enrollment, endpoint results and safety findings from SAPPHIRE, and whether the planned 2024 readout and conditional 2025 launch remain achievable.
- Cash burn and runway assumptions, financing needs, and the conditions and availability of additional debt tranches or the $100 million at-the-market program.
- Potential dilution: the June 2022 offering included 27.7 million pre-funded warrants and 10.5 million common warrants; compare these securities with reported shares outstanding and subsequent filings.
- How much weight to place on TOPAZ extension data and early DRAGON results, given their study designs, populations and preliminary status.
- Manufacturing continuity and intellectual-property exposure, including the single-source supply arrangement and the two ongoing European patent oppositions.